FML-spinoff hemotune AG receives grant from Innosuisse

FML spin-off hemotune AG together with ETH Zurich and external pageWyss Zurichcall_made received an Innosuisse grant worth CHF 580’000, to further advance hemotune’s sepsis treatment. The grant supports the development of hemotune’s magnetic blood purification that selectively removes multiple key drivers of sepsis. Sepsis is a dysregulated immune response to infection with globally 11 million deaths. Its most severe form septic shock has mortality rates of 30-50%.

hemotune’s treatment is designed to restore adequate immune function in septic shock patients and to improve their outcomes. external pageInnosuissecall_made, the Swiss Innovation Agency, supports innovation projects between research institutes and industry that benefit the Swiss economy and society.

For more information, visit hemotune’s website: external pagewww.hemotune.chcall_made